Ginkgo Bioworks Holdings (DNA) Income from Continuing Operations (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Income from Continuing Operations came in at 76059000.0 in Q1 2026, up 8.7% YoY from 69969140.03 in Q1 2025, and up 5.81% on a QoQ basis from 80751000.0 in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Income from Continuing Operations data on file, last reported at 76059000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 8.7% year-over-year to 76059000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 297865000.0 (up 35.86% YoY) and the FY2025 annual result came in at 312763000.0, up 42.83% from the prior year.
- Income from Continuing Operations rose to 76059000.0 in Q1 2026, from 80751000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 56403000.0 in Q3 2024 to a low of 670570000.0 in Q2 2022.
- A 5-year average of 231026176.47 and a median of 173078000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 89.22% in 2022, down 1131.22% in 2022.
- Tracing DNA's Income from Continuing Operations over 5 years: stood at 173078000.0 in 2022, then fell by 22.31% to 211694000.0 in 2023, then surged by 49.2% to 107534000.0 in 2024, then gained by 24.91% to 80751000.0 in 2025, then climbed by 5.81% to 76059000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 76059000.0 (Q1 2026), 80751000.0 (Q4 2025), and 80755000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | -57.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -57.32 Mn |
| Mar 31, 2026 | -76.06 Mn |
| Dec 31, 2025 | -80.75 Mn |
| Sep 30, 2025 | -80.76 Mn |
| Jun 30, 2025 | -60.30 Mn |
| Mar 31, 2025 | -83.31 Mn |
| Dec 31, 2024 | -107.53 Mn |
| Sep 30, 2024 | -56.40 Mn |
| Jun 30, 2024 | -217.18 Mn |
| Mar 31, 2024 | -165.91 Mn |
| Dec 31, 2023 | -211.69 Mn |
| Sep 30, 2023 | -302.89 Mn |
| Jun 30, 2023 | -173.32 Mn |
| Mar 31, 2023 | -204.97 Mn |
| Dec 31, 2022 | -173.08 Mn |
| Sep 30, 2022 | -670.13 Mn |
| Jun 30, 2022 | -670.57 Mn |
| Mar 31, 2022 | -592.59 Mn |
| Dec 31, 2021 | -1.60 Bn |
| Sep 30, 2021 | -102.41 Mn |